Picture of BrightPath Biotherapeutics Co logo

4594 BrightPath Biotherapeutics Co Share Price

0.000.00%
jp flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-17.51%
3m-31.93%
6m-59.04%
1yr-74.95%
Volume Change (%)
10d/3m+136.52%
Price vs... (%)
52w High-64.32%
50d MA-15.49%
200d MA-39.46%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value6.02
Price to Tang. Book6.02
Price to Free Cashflown/a
Price to Sales39,399.37
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-145.74%
Return on Equity-93.38%
Operating Margin-1025914.41%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202431st Mar 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of BrightPath Biotherapeutics Co EPS forecast chart

Profile Summary

BrightPath Biotherapeutics Co., Ltd. is a Japan-based company mainly engaged in the development of pharmaceutical products. The Company is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The Company also generates the revenues from license fees from the pharmaceutical companies.

Directors

Last Annual
March 31st, 2023
Last Interim
December 31st, 2023
Incorporated
May 8th, 2003
Public Since
October 22nd, 2015
No. of Shareholders
28,649
No. of Employees
32
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
jp flag iconTokyo Stock Exchange
Shares in Issue
70,441,299

4594 Share Price Performance

Upcoming Events for 4594

Dividend For 4594.T - 0.0000 JPY

Full Year 2024 BrightPath Biotherapeutics Co Ltd Earnings Release

Similar to 4594

Picture of 3-D Matrix logo

3-D Matrix

jp flag iconTokyo Stock Exchange

Picture of AnGes logo

AnGes

jp flag iconTokyo Stock Exchange

Picture of Carna Biosciences logo

Carna Biosciences

jp flag iconTokyo Stock Exchange

Picture of Chiome Bioscience logo

Chiome Bioscience

jp flag iconTokyo Stock Exchange

Picture of Cyfuse Biomedical KK logo

Cyfuse Biomedical KK

jp flag iconTokyo Stock Exchange

FAQ

0